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Background and Objectives.E x t e n d e ds p e c t r u mβ-lactamase (ESBL) production is increasing all over the world, and organisms
other than E. coli and K. pneumoniae are acquiring this character. ESBL production is detectable by automation, E-test, double
disk diﬀusion (DDD), and PCR. This study aimed to determine the prevalence of ESBL production among clinical isolates of
gram-negative rods, and to evaluate the eﬀectiveness of augmentation of clavunate with Cefotaxime, Ceftazoxime, Aztreonam,
Ceftriaxone, and Cefpodoxime in detecting ESBL production. Methods. 472 clinical gram-negative isolates identiﬁed by standard
methods were tested for ESBL-production by (DDD) method using six cephalosporins and amoxicillin-clavulinate discs. Results.
108/472 (22.9%) of the isolates were ESBL producers, and were prevalent in tertiary care hospitals. 88.2% of E. cloacae, 71.4% of K.
pneumoniae, 28.6% of K. oxytoca, 12.5% of C. freundii, 11.1% of A. calcoacceticus, and 10.8% of E. coli were ESBL producers. The
DDD test demonstrated some variations in the eﬃcacy of the diﬀerent cephalosporins in detecting all the ESBL producers. The
inclusion of ceftizoxime discs increased the eﬃcacy of the test. It is concluded that ESBL-producing bacteria were prevalent among
our hospitalized patients, and involved genera other than Klebsiella and Escherichia, and the inclusion of ceftizoxime increased the
eﬃcacy of ESBL detection by the DDD test.
Copyright © 2009 Raymond G. Batchoun et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Among the family Enterobacteriacae, the production of
plasmid-mediated extended-spectrum β-lactamase (ESBLs)
has emerged as an important mechanism of resistance to
β-lactam drugs that account for approximately 50% of
antibiotic consumption [1]. The vast majority of ESBLs are
derivatives of TEM-1 and TEM-2 chromosomally encoded
enzyme of Klebsiella pneumoniae [2]. These enzymes are
capable of hydrolyzing a wide range of β-lactams, including
most recently developed cephalosporins, but are not active
against cephamycins and carapenems [3]. In interpreting the
phenotype of ESBL-positive strains with regard to β-lactams,
it should be borne in mind that drug resistance may also
result from the combined activity of a speciﬁc ESBL together
with other β-lactamases (the chromosomal AmpC) [3], or
the plasmid-borne one [4].
Among Enterobacteriacae, ESBLs have been found
mainly in Klebsiella spp. and Escherichia coli,b u th a v eb e e n
also reported in other genera world wide, such as Citrobacter,
Enterobacter, Morganella, Proteus, Providencia, Salmonella,
Serrati, and Pseudomonas [5–9].
Infections caused by ESBL-producing bacteria often
involve immune-compromised patients, making it diﬃcult
to eradicate these organisms in high-risk wards, such as
intensive care unites [10, 11].
Microbiology laboratories play an important role
in detecting and promptly reporting the isolation of
ESBL-positive bacteria, especially AmpC beta-lactamases-
producing ones that complicate therapy and limit treat-
ment options [12]. Drug susceptibility data are of major
importance for the clinical management of patients infected
by these organisms [13]. Reduced susceptibility or increase
in resistance to extended-spectrum cephalosporins and/or2 International Journal of Microbiology
monobactams represents the ﬁrst indicator of ESBL pro-
duction, but conﬁrmation is dependent on synergy between
clavulanate and the selected β-lactams, using double-
disk diﬀusion method, or E-test [14]. The expression of
an extended-spectrum enzyme does not always involve
a phenotype that can be interpreted as resistant by the
routine MICs and disk diﬀusion methods that follow
current National Committee for Clinical Laboratory Stan-
dards/recently named Clinical and Laboratory Standards
Institute (NCCLS/CLSI) breakpoint. Accordingly, ESBL-
positive strains should be reported as resistant even if drug
MICs are below breakpoints established for cephalosporins
and aztreonam. This is deﬁned for both Klebsiella spp, and
E.coli, but not established for the other Enterobacteriaceae
[15].
When detecting ESBL-positive strains, microbiology lab-
oratories should provide the clinician with reliable therapeu-
tic options for successfully treating infected patients, since
ESBL-distribution has been shown to diﬀer among countries
[3,6,16].Thusmonitoringoftheprevalenceandthetypesof
extended spectrum β-Lactamase enzymes may contribute to
deﬁning the degree of the problem in a speciﬁc geographical
area, and establishing a proper treatment protocol.
Before the emergence and increased spread of ESBL-
producing gram-negative bacteria, most infections could
be reliably treated with second- and third-generation
cephalosporins. However, ESBL-producing organisms are
spreading world wide, resulting in the failure of empiric
therapy dependent on second- and third-generation
cephalosporins which complicate infections in immune-
compromised patients, neonates, the elderly, debilitated
patients, nosocomial infections, and outbreaks occurring in
hospital setting [17–22].
The aim of this study was to assess the prevalence of
ESBL-producing gram-negative organisms among diﬀerent
bacterial genera and species isolated from clinical cases from
three major hospitals in northern Jordan, and to assess
the eﬀectiveness of clavulanate and six cephalosporins in
detecting ESBL production.
2.MaterialsandMethods
2.1. Bacterial Isolates. A number of 472 gram-negative
bacterial isolates recovered from 463 patients were included
in this study. These isolates were isolated from clinical
specimens at the microbiology laboratories in three hospitals
in northern Jordan during ten-month period (January–
October 2004). These hospitals were King Abdullah Uni-
versity Teaching Hospital (KAUTH) (tertiary care hospital),
Princess Basma Teaching Hospital (PBTH) (primary and
secondary care hospital), and Princess Rahmeh Teaching
Hospital(PRTH)(secondarycarehospitaldealingwithpedi-
atrics, neonates, obstetrics and gynecology, and immune-
suppressed patients). Gram-negative bacteria belonging to
the genera Escherichia, Klebsiella, Proteus, Citrobacter, Enter-
obacter, Serratia, Pseudomonas, Acinetobacter, Alkaligenes,
and Stenotrophemonas were included in the study. These
bacteria were isolated from various clinical specimens such
as blood culture, urine, CSF, sputum, wound, pus, ear swabs,
eye swabs, peritoneal ﬂuid, and other miscellaneous sources.
These isolates were recovered from the specimens by being
culturedonthespeciﬁcmedia,undertheoptimalconditions,
and were identiﬁed to genus and species using standard
methods(conventionalmanualmethods,Rapid-ID—Remel,
USA, and Vitek automation technology) [23–25]. Multiple
samplesorisolatesfromthesamepatientwereexcludedfrom
thestudy.Theseisolatedwerestoredonsimplestoragemedia
as described by Evans et al. in 1977 [26].
2.2. ESBL Production. Test organisms from stock culture
were activated by inoculation in to Mueller Hinton broth
(BD, USA) and incubated at 37
◦C for 24 hours. The
concentration of the bacterial suspension was adjusted to be
equivalent to 0.5 McFarland standards. The test organism
was seeded on the surface of freshly prepared Mueller
Hinton agar (BD, USA), in three directions using a sterile
Dacron swab, according to the recommendations of Kirby-
Bauer Disk Diﬀusion method [25], and NCCLS (CLSI)
guide lines [27]. The plates were allowed to stand at room
temperature for 15 minutes prior to the application of
antibiotic containing disks.
ESBL-producing isolates were detected using the Double
Disk Diﬀusion method (Double Disk Approximation Test)
[28]. Six antibiotic disks (Cefotaxime 30ug, Ceftazidime
30ug, Ceftriaxone 30ug, Cefpodoxime 10ug, Ceftizoxime
30ug, and Aztreonam 30ug) (Oxoid, UK) were placed
around a central disk of Amoxicillin-Clavulanic acid 30ug
(20:10resp.)(Oxoid,UK),30mmcentertocenteronMueller
Hinton agar plates seeded with organism being tested for
ESBL production.
Plates were incubated aerobically at 37
◦C for 18–24
hours, and the diameter of the inhibition zone (if any)
around the antimicrobial disks was measured in mm using a
ruler. Any augmentation (increase in diameter of inhibition
zone) between the central Amoxicillin-Clavulanic acid disk
and any of the six antibiotic disks showing resistance or
intermediate susceptibility was recorded, and the organism
w a st h u sc o n s i d e r e da sa nE S B Lp r o d u c e r .
3. Results
3.1. Distribution of Bacterial Species with Sample Source.
Urine was the major source of the bacterial isolates collected,
comprising 262/472 (56%) of the total isolates, blood culture
79/472 (16.7%), swabs from various sites 80/472 (16.9%),
CSF 16/472 (3.3%), sputum 8/472 (1.6%), and the other
miscellaneous sources 44/472 (5.5%) (Table 1).
Escherichia coli was the most common species isolated
from these specimens, comprising 195/472 (41.4%). This
organism was the major isolate recovered from urine sam-
ples, representing 171/195 (87.7%) of the total E. coli isolates
from the three teaching hospitals (Table 1).
Genus Klebsiella was the second isolated pathogen from
the tested samples, constituting 132/472 (28%) of the total
isolates, of which Klebsiella pneumonia represented 84/472
(17.8%) of the total isolates. However, 48/84 (57%) of theInternational Journal of Microbiology 3
Table 1: Bacterial species isolated from clinical samples.
Bacterial species Blood
culture CSF Sputum Swab Urine Miscellaneous Total
Acinetobacter baumannii 22
Acinetobacter calcoaceticus 61 2 9
Acinetobacter lwoﬃi 1 1
Acinetobacter species 1 2 126
Alcalgenes xylosoxidans 11
Citrobacter frundii 11 6 8
Escherichia coli 6 1 13 171 4 195
Enterobacter aerogenes 11
Enterobacter cloacae 11 1 5 17
Enterobacter hormaechei 112
Enterobacter species 74 1 1 2
Klebsiella pneumoniae 1 8 19 28
Klebsiella oxytoca 4 8 1 2 9 2 138 4
Proteus mirabilis 6 1 612 3
Pseudomonas aeruginosa 4 12 3 24 10 11 64
Pseudomonas species 11 0 4 1 1 6
Serratia marcescens 11
Stenotrophemonas
maltophilia 22
Total 79 16 8 80 262 27 472
Miscellaneous: Aspirate, Bone, Cornea, Peritoneal, Tissues, Tracheostomy.
Klebsiella pneumoniae isolates were recovered from blood
culture, 21/84 (25%) from urine, and the remaining 15/84
(18%) from sputum and the other miscellaneous sources.
Similarly, Klebsiella oxytoca comprised 28/472 (5.9%) of the
total isolates, of which 19/28 (67.9%) were isolated from
urine, and the remaining 9/28 (32.1%) were detected at low
frequency from the specimens (Table 1).
Pseudomonas aeruginosa represented 64/472 (13.5%) of
the total isolates, where 24/64 (37.5%) of these pseudomonas
aeruginosa were isolated from swabs of various sources,
12/64 (18.8%) from Cerebrospinal ﬂuid (CSF), 10/64
(15.6%) from urine, and the remaining 18/64 (28.1%) were
from the other miscellaneous sources (Table 1). Additionally,
16/472 (3.4%) pseudomonas spp other than Pseudomonas
aeruginosa were isolated mainly from various swabs, urine,
and the other miscellaneous samples.
Proteus mirabilis isolates represented 23/472 (4.8%) of
the bacterial isolates, where 16/23 (69.5%) of them were
isolatedfromurinesamples,7/23(30.4%)fromswabsofvar-
ious sources and other miscellaneous specimens (Table 1).
Genus Enterobacter was common among the gram-
negative isolates constituting 32/472 (7.8%) of the isolates.
Enterobacter cloacae was the major species isolated constitut-
ing 11/17 (64.7%) of the Enterobacter recovered from blood
cultures, 5/17 (29.7%) from urine cultures, and 1/17 (5.9%)
from sputum samples. The other 14 Enterobacter spp were
isolated from swabs of various sources and urine (Table 1).
Bacterial isolates belonging to the genus Acinetobac-
ter (Acinetobacter baumannii, Acinetobacter calcoaceticus,
Acinetobacter lwoﬃi, and other Acinetobacter spp)c o n -
stituted 18/472 (3.8%) most of which were recovered
from blood culture, sputum, and miscellaneous sources.
Other gram-negative bacterial species, including Citrobac-
ter frundii, Serratia marcescens, Alkaligenes xylosoxidans,
and Stenotrophomonas maltophilia, collectively represented
12/472 (2.5%), most of which were isolated from urine
samples (Table 1).
3.2. ESBL Production. The Double Disk diﬀusion test
revealed that out of the 472 gram-negative isolates included
in the study, 108 isolates were ESBL producers. These ESBL-
producing bacteria belonged to 8 diﬀerent species out of the
18 species isolated from the clinical samples from the three
teaching hospitals (Table 2).
ESBL production was very common among Klebsiella
pneumoniae, where out of the 84 Klebsiella pneumoniae
isolates, 49 (71.4%) were ESBL producers. However, within
Klebsiella oxytoca isolates, only 8 out of 28 isolates were
ESBL-producers, representing only 28.5%. On the other
hand,ESBLproductioninE.coliwasfoundin21/195isolates
representing only 10.8% (Table 2).
Out of the 17 Enterobacter cloacae isolated, 15 (88.2%)
were ESBL producers, and all of them were recovered
from blood culture and urine culture from KAUTH during
Enterobacter cloacae outbreak (Table 2).
ESBL production in Citrobacter frundii was found only
in one isolate out of the 8 isolates (12.5%) recovered from4 International Journal of Microbiology
Table 2: ESBL production among the gram-negative bacteria.
Acinetobacter
calcoaceticus
Citrobacter
frundii
Escherichia
coli
Enterobacter
cloacae
Enterobacter
hormaechei
Klebsiella
oxytoca
Klebsiella
pneumoniae
Stenotrophemonas
maltophilia
Total isolate 9 8 195 17 2 28 84 2
Number ESBL
producer 1 1 21 15 1 8 60 1
Percentage ESBL
producer/species 11.1 12.5 10.8 88.2 50 28.6 71.4 50
KAUTH. Similarly, only one Acinetobacter calcoaceticus out
of the nine isolates was ESBL producer. None of the other
Acinetobacter spp. isolated produced ESBL (Table 2). Further
more, one isolate of both Enterobacter hormaechei and
Stenotrophemonas maltophilia was ESBL producer (Table 2).
Most of the ESBL-producing isolates were recovered from
patients samples collected from the tertiary care KAUTH.
3.3. Eﬀectiveness of Antibiotics Used in Detecting ESBL
Production. The most important feature in detecting ESBL-
producing isolates by the Double Disk Diﬀusion method
is the formation of augmentation of the bacterial growth
inhibition zone between the central Amoxicillin-Clavulanic
acid (AMC) disk and the surrounding cephalosporin’s ones.
The 21 ESBL-producing Escherichia coli isolates gave the
highest number of augmentation zones when Cefotaxime
(CTX)andCeftizoxime(ZOX)diskswereused.Bothofthese
antibiotics were successful in identifying 20/21 (95.2%) of
the ESBL producers. Augmentation with Aztreonam (ATM)
detected 18/21 (85.7%) ESBL-producing E. coli, Ceftazidime
(CAZ) 15/21 (71.4%), Ceftriaxone (CRO) 11/21 (52.4%),
and Cefpodoxime (CPD) 4/21 (19%) (Table 3).
ESBL-producing Enterobacter cloacae, which were col-
lected during an out break in KAUTH, had little variation in
the antibiogram of the isolates suggesting a common source.
Disks used in the detection of ESBL were closely successful
in detecting ESBL production, where ATM was capable of
detecting all of the 15 ESBL producing isolates, followed
by CTX and CRO which detected 14/15 (93.3%) of them.
Both CAZ and ZOX detected only 13/15 (86.7%), while
CPD detected only 12/15 (80%) of the ESBL-producing
Enterobacter cloacae (Table 3).
Klebsiella pneumoniae isolates producing ESBL gave
augmentation with ZOX, where it detected 57/60 (95%)
of the ESBL-producing isolates, CTX 49/60 (81.7%), ATM
43/60 (71.7%), CAZ 30/60 (60%), CRO 26/60 (43.3%), and
CPD 15/60 (16.7%), respectively, (Table 3). Similarly, out of
the 8 ESBL-producing Klebsiella oxytoca,Z O Xd e t e c t e d7 /8
(87.5%) of the ESBL producers, ATM 6/8 (75%), CTX 4/8
(50%), CAZ 3/8 (37.5%), and CRO 2/8 (25%), respectively,
(Table 3).
On the contrary, eﬀectiveness of the antibiotics used
in the detection of ESBL production in Acinetobacter cal-
coaceticus, Citrobacter frundii, Enterobacter hormaechei, and
Stenotrophemonas maltophilia could not be established due
tothesmallnumberofESBL-producingisolatesamongthese
species (Table 3).
4. Discussion
This study included three major hospitals in northern
Jordan, to assess the prevalence and distribution of ESBL-
positive species among Enterobacteriaceae and other gram-
negative bacteria recovered from clinical specimens, and
evaluated the eﬃcacy of diﬀerent cephalosporins in the
detection of ESBL production.
In a study between 1990 and 1993, Youssef et al., in
1999 reported that 38% of Klebsiella pneumoniae isolates
were ESBL producers [29]. Shehabi et al., in 1999 reported
an incidence of ESBL production in Klebsiella pneumoniae
and Escherichia coli isolates in the ICU of Jordan University
Hospital, to be 70% and 38%, respectively, [30]. Batchoun
and Matalka (unpublished data) did not detect any ESBL
producers among various pseudomonas species.
Extended-spectrum β-lactamases (ESBLs) are enzymes
capable of hydrolyzing oxyimino-cephalosporins, such as
Cefotaxime (CTX), Ceftriaxone, Ceftazidime (CAZ), and
monobactams (e.g., aztreonam (ATM)), thereby causing
resistance to these drugs. The enzymes are detected most
commonly in Klebsiella pneumoniae and Escherichia coli but
have been noted in other members of the family Enter-
obacteriaceae as well [22]. The majority of these enzymes
usually have only 1, 2, or 3 amino acid mutation from
those of the parent enzymes (TEM-1, TEM-2, and SHV-1).
These mutations are thought to have evolved under selective
pressures exerted by antibiotic treatment, and continued
use of cephalosporin antibiotics. The fact that most of
these enzymes are carried by plasmids has facilitated the
spread of ESBL enzymes among members of the family
Enterobacteriaceae and other gram-negative bacteria, and
single strain of K. pneumoniae or E. coli may harbor diﬀerent
variants of ESBL genes such as SHV with CTX-M type,
AmpCormetalo-β-lactamasestogether,thatmaycomplicate
therapy [31].
In our study, urine was the source of 262/472 (56%) of
the isolates, indicating that UTI is a common illness in our
community. Blood culture (16.7%, 79/472) was the second
major source of isolates thus indicating the relatively high
frequency of gram-negative bacteria involved in bacteremias
orsepticemiasinhospitalizedpatients.Therestoftheisolates
collected in our study were from ear swabs, swabs from
miscellaneous sources, CSF, and sputum.
Outofthe472isolatesrecoveredinthisstudy,195isolates
were E. coli and 84 were K. pneumoniae.B o t hE. coli and
K. pneumoniae are involved world wide in ESBL production,
however, as major isolates from our hospitals, they can give
us a good picture about ESBL production in our community.International Journal of Microbiology 5
Table 3: Eﬃcasy of cephalosporins in detecting ESBL-producers.
Species (count) Interpretation AMC CTX CAZ ATM CRO ZOX CPD CTT FEP CXM CFP
Acinetobacter calcoaceticus (1)
S 11 1 1
I 11
R 11 1 1 1
A 111111 111
Citrobacter frundii (1)
S 1
I
R 1111111 111
A1 1 1
Escherichia coli (21)
S 76 8 2 1 4
I 11 3 4 4 3 9 6 1 1
R 3 18 11 17 18 4 21 11 20 20
A2 0 1 5 1 8 1 1 2 0 4 7 1 8 4 1 1
Enterobacter cloacae (15)
S 12 3 12 1
I 12 1 12 2 1 1 11
R 15 3 14 15 3 1 15 11 2 15 3
A 14 13 15 14 13 12 1 15 12 13
Enterobacter hormaechei (1)
S
I 1
R 11111 1 111
A1
Klebsiella oxytoca (8)
S 12 7 1
I 51 131 1
R 3867838 688
A4 3 6 2 7 6 4
Klebsiella pneumonia (60)
S 8 27 1 31 60 17 1
I 37 16 9 2 15 29 8 5 9
R 15 44 24 57 49 60 35 54 51
A 4 93 64 32 65 71 51 0 4 61 13 1
Stenotrophemonas maltophilia (1)
S 111 1 1 1
I 11
R 11 1
A1 1 1 1
AMC: Amoxicillin-Clavulanic Acid, CTX: Cefotaxime, CAZ: Ceftazidime, ATM: Aztreonam, CRO: Ceftriaxone, ZOX: Ceftizoxime, CPD: Cefpodoxime, CTT:
Cefotetan, FEP: Cefepime, CXM: Cefuroxime, and CFP: Cefoperazone, S: Sensitive, I: Intermediate, R: Resistant, A: Augmentation.
Other clinically important isolates that include Pseu-
domonas aeruginosa (64/472), Klebsiella oxytoca (28/472),
Proteus mirabilis (23/472),Enterobactercloacae(17/472),and
PseudomonasSpp(16/472)wererecoveredinmoderatenum-
ber, whereas the remaining isolates were scarce. Although
the moderate number of these isolates is high enough to
allowacalculationofthepercentageofESBLproduction,this
percentage may not actually reﬂect the true nature of ESBL
production in the isolate nation wide, and may only indicate
the presence of an endemic bacteria in a speciﬁc hospital or
a speciﬁc ward. This is certainly true—if not at least—for
the17isolatesofEnterobactercloacaewhichwereallcollected
from King Abdullah University Teaching Hospital during an
outbreak.
In regard to ESBL production, one of the most alarming
ﬁndings of this study is the ESBL production in 60/84
(72.4%) of the Klebsiella pneumoniae isolates. This percent-
age is considered to be very high compared to prevalence
of ESBL production world wide among this species when
compared with the 20% prevalence of the Italian study [32],
and39.5%intheChinesestudy[33],11.3%inSaudiArabian
study [34], and 13.3% in the Kuwaiti study [35]. However,
our results are matching previous Jordanian study which
reported that 70% of the K. pneumoniae isolates recovered
from the ICU of Jordan University Hospital to be ESBL
producers [30]. On the other hand, none of the Klebsiella
pneumoniaeisolatesrecoveredfromPrincessBasmaTeaching
Hospital were ESBL producer, which may be attributed to
the low number of isolates recovered, the nature of the
hospital type, and the patients being served. On the contrary,
Isolates from Princess Rahma Teaching Hospital and King
Abdullah University Teaching Hospital showed ESBL pro-
duction in 35/39 (89.7%) and 25/32 (78.1%), respectively.
The abnormally high percentage of ESBL production in6 International Journal of Microbiology
these two hospitals may indicate the presence of a previously
undetected source of a nosocomial infection, the nature of
patients being served as both hospitals are serving debilitated
patients,andasreferralhospitalsformalignancyandchronic
diseases. Such ﬁndings impose the need for applying speciﬁc
infection control measures to eliminate this organism.
One of the highest ESBL producers by percentage was
found to be Enterobacter cloacae, which was found in 15/17
collected isolates, thus constituting 88.2%. As indicated
before, this high percentage disagrees with prevalence of
ESBLproductioninthisspecieswhichwas2.9%intheItalian
study [32], 6% in the Chinese study [33], and 12.8% in the
Korean study [8]. This observation could only be explained
on the fact that all these Enterobacter cloacae isolates were
recovered from King Abdullah University Teaching Hospital
during a period of outbreak, as supported by their semi-
identical antibiogram proﬁles and DDD test results.
InEscherichiacoliisolates,ESBLproductionwasfoundin
21 out of a total of 195 isolates recovered (10.8%). This per-
centage agrees with the Chinese study, which demonstrated
ESBL production in 11.4% of their Escherichia coli isolates
[33], the Saudi Arabian study (9.6%) [34], and the Kuwaiti
study (11.7%) [35], but higher than that of the Italian study
(1.2%) [32], and lower than the Taiwanese one [11]. It is
worth noting that most ESBL-producing E. coli isolates were
from King Abdullah University Teaching Hospital, whereas
those from PBTH and PRTH did not exceed 6%.
In Klebsiella oxytoca isolates, ESBL production was found
in 8/28 (28.5%) of the isolates recovered. This percentage
(although the sample size is not large enough) is considered
to be high when compared to those for Klebsiella oxytoca
worldwide, where the Italian study reported 15% prevalence
[32]. It is also worth noting that isolates from KAUTH
showed the highest degree of ESBL production (80%,
4/5), whereas PRTH and PBTH showed ESBL production
in 2/9 isolates (22.2%), and 2/14 (14.3%), respectively.
Furthermore, ESBL started to appear among Citrobacter
frundii, Acinetobacter calcoaceticus, Enterobacter hormaechei,
and Stenotrophemonas maltophilia isolates from the tertiary
care hospital KAUTH, which may reﬂect the expansion of
the genes coding for ESBLs production to other bacterial
genera. Although their prevalence in our samples is not
high, however, these organisms are becoming a threat to ICU
patients and becoming involved in nosocomial infections
as reported in Taiwanese, Bulgarian, and Korean hospitals
[8, 9, 11].
The NCCLS (CLSI) [27] recommend testing for ESBL
production using CTX, CAZ, ATM, CRO, and CPD in
combination with AMC. In our study, we have evaluated the
eﬀectiveness of each of the above antibiotics in addition to
ZOX in detection of ESBL production by the DDD method.
In Escherichia coli, both CTX and ZOX detected 20/21
(95%) of the ESBL-producing isolates, whereas ATM
detected only 85.7% of the isolates. However, CAZ, CRO,
C P Dw e r en o te ﬃcient in detecting ESBL-producing E. coli.
Similarly, ZOX, CTX, and ATM were eﬃcient in detecting
95%, 81.7%, 71.7% ESBL-producing Klebsiella pneumonia,
respectively. The other antibiotics could detect few ESBL-
producing K. pneumoniae.
In Klebsiella oxytoca, ZOX showed excellent performance
by detecting 7/8 (87.5) of the ESBL-producing isolates. ATM
detected 75% of the isolates, while the other antibiotics
detected only 50% or less of the ESBL-production in the
isolates.
In Enterobacter cloacae,C T Xa n dC R Op e r f o r m e de x c e l -
lently by detecting 14/15 (93.3%) of the ESBL producing
isolates, whereas CAZ and ZOX detected 13/15 (86.7%) of
the ESBL producers, while CPD detected only 12/15 (80%)
of them.
In conclusion, ESBL-producing gram negative bacteria
constituted 22.9% (108/472) of all recovered isolates, and
were prevalent among E. coli, K. pneumoniae, K. oxytoca,
Enterobacter cloacae, especially from samples collected from
patients in secondary and tertiary care hospitals. The
inclusion of ceftizoxime (ZOX) to the ESBL-detection panel
will increase the eﬃcacy of the DDD test in detecting ESBL
producers.
Acknowledgment
The authors would like to thank the Faculty of Scientiﬁc
Research at Jordan University of Science and Technology for
the ﬁnancial funding of this study.
References
[1] R. Bonnet, C. De Champs, D. Sirot, C. Chanal, R. Labia,
and J. Sirot, “Diversity of TEM mutants in Proteus mirabilis,”
Antimicrobial Agents and Chemotherapy, vol. 43, no. 11, pp.
2671–2677, 1999.
[2] G. Arlet, G. Brami, D. Decrere, et al., “Molecular characteri-
zation by PCR-restriction fragment length polymorphism of
TEM β-lactamases,” FEMS Microbiology Letters, vol. 134, pp.
1498–1500, 1995.
[3] J. Blazquez, M. I. Morosini, M.-C. Negri, and F. Baquero,
“Selection of naturally occurring extended-spectrum TEM β-
lactamase variants by ﬂuctuating β-lactam pressure,” Antimi-
crobial Agents and Chemotherapy, vol. 44, no. 8, pp. 2182–
2184, 2000.
[4] J. Walther-Rasmussen and N. Høiby, “Plasmid-borne AmpC
β-lactamases,” Canadian Journal of Microbiology, vol. 48, no.
6, pp. 479–493, 2002.
[5] G. Arlet and A. Philippon, “ Construction by polymerase
chain reaction and intragenic DNA probes for three main
typesoftransferableβ-lactamases(TEM,SHV,CARB),”FEMS
Microbiology Letters, vol. 82, pp. 19–26, 1991.
[6] A. Bauernfeind, I. Stemplinger, R. Jungwirth, S. Ernst, and
J. M. Casellas, “Sequences of β-Lactamase genes encoding
CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their
amino acid sequences with those of other β-lactamases,”
Antimicrobial Agents and Chemotherapy, vol. 40, pp. 509–513,
1996.
[7] W. -L. Yu, Y. -C. Chuang, and J. Walther-Rasmussen,
“Extended-spectrum beta-lactamases in Taiwan: epidemiol-
ogy, detection, treatment and infection control,” Journal of
Microbiology, Immunology and Infection,v o l .3 9 ,n o .4 ,p p .
264–277, 2006.
[8] S. H. Choi, J. E. Lee, S. J. Park, et al., “Prevalence, micro-
biology, and clinical characteristics of extended-spectrumInternational Journal of Microbiology 7
β-lactamase-producing Enterobacter spp., Serratia marcescens,
Citrobacter freundii,a n dMorganella morganii in Korea,” Euro-
pean Journal of Clinical Microbiology and Infectious Diseases,
vol. 26, no. 8, pp. 557–561, 2007.
[9] D. Ivanova, R. Markovska, N. Hadjieva, I. Schneider, I.
Mitov,andA.Bauernfeind,“Extended-spectrumβ-lactamase-
producing Serratia marcescens outbreak in a Bulgarian hos-
pital,” Journal of Hospital Infection, vol. 70, no. 1, pp. 60–65,
2008.
[10] R. Bonnet, J. L. M. Sampaio, C. Chanal, et al., “A novel
class A extended-spectrum β-lactamase (BES-1) in Serra-
tia marcescens isolated in Brazil,” Antimicrobial Agents and
Chemotherapy, vol. 44, no. 11, pp. 3061–3068, 2000.
[ 1 1 ]J .J .J e a n ,P .R .H s u e h ,W .S .L e e ,e ta l . ,“ N a t i o n w i d es u r v e i l -
lance of antimicrobial resistance among Enterobacteriaceae in
intensive care units in Taiwan,” European Journal of Clinical
Microbiology and Infectious Diseases, vol. 28, no. 2, pp. 215–
220, 2009.
[12] J. F¨ arber, K. A. Moder, F. Layer, I. Tammer, W. K¨ onig, and
B. K¨ onig, “Extended-spectrum beta-lactamase detection with
diﬀerent panels for automated susceptibility testing and with
a chromogenic medium,” Journal of Clinical Microbiology, vol.
46, no. 11, pp. 3721–3727, 2008.
[ 1 3 ]K .B u s h ,G .A .J a c o b y ,a n dA .A .M e d e i r o s ,“ Af u n c t i o n a l
classiﬁcation scheme for β-lactamases and its correlation with
molecular structure,” Antimicrobial Agents and Chemotherapy,
vol. 39, no. 6, pp. 1211–1233, 1995.
[14] F. H. M’Zali, A. Chanawong, K. G. Kerr, D. Birkenhead, and
P. M. Hawkey, “Detection of extended-spectrum β-lactamases
in members of the family Enterobacteriaceae: comparison of
t h eM A S TD Dt e s t ,t h ed o u b l ed i s ka n dt h eE t e s tE S B L , ”
Antimicrobial Agents and Chemotherapy, vol. 45, pp. 881–885,
2000.
[15] R. A. Bonomo, S. A. Rudin, and D. M. Shlaes, “Tazobactam
is a potent inactivator of selected inhibitor-resistant class A β-
lactamases,”FEMSMicrobiologyLetters,vol.148,no.1,pp.59–
62, 1997.
[16] P. A. Bradford, Y. Yang, D. Sahm, I. Grope, D. Gardovska,
and G. Storch, “CTX-M-5, a novel cefotaxime-hydrolyzing β-
Lactamase from an out-break of Salmonella typhimurium in
Latvia,” Antimicrobial Agents and Chemotherapy, vol. 42, pp.
1980–1894, 1998.
[ 1 7 ]C .B r a n g e r ,A .L .L e s i m p l e ,B .B r u n e a u ,P .B e r r y ,a n dN .
Lambert-Zechovsky, “Long-term investigation of the clonal
dissemination of Klebsiella pneumoniae isolates producing
extended-spectrum β-lactamases in a university hospital,”
Journal of Medical Microbiology, vol. 47, no. 3, pp. 201–209,
1998.
[ 1 8 ]P .L .H o ,D .N .C .T s a n g ,T .L .Q u e ,M .H o ,a n dK .Y .
Yuen, “Comparison of screening methods for detection of
extended-spectrum β-lactamases and their prevalence among
Escherichia coli and Klebsiella species in Hong Kong,” APMIS,
vol. 108, no. 3, pp. 237–240, 2000.
[19] H. Pai, S. Lyu, J. H. Lee, J. Kim, Y. Kwon, J.-W. Kim, and K. W.
Choe, “Survey of extended-spectrum β-lactamases in clinical
isolates of Escherichia coli and Klebsiella pneumoniae:p r e v a -
lence of TEM-52 in Korea,” Journal of Clinical Microbiology,
vol. 37, no. 6, pp. 1758–1763, 1999.
[20] T. Yagi, H. Kruokawa, N. Shibata, K. Shibayama, and Y.
Arakawa, “A preliminary survey of extended-spectrum β-
lactamases(ESBLs)inclinicalisolatesofKlebsiellapneumoniae
and Escherichia coli in Japan,” FEMS Microbiology Letters, vol.
184, pp. 53–56, 2000.
[21] J. J. Yan, S. M. Wu, S. H. Tsai, J. J. Wu, and I. J. Su, “Prevalence
of SHV-12 among clinical isolates of Klebsiella pneumoniae
producingextended-spectrumβ-lactamasesandidentiﬁcation
of a novel AmpC enzyme (CMY-8) in southern Taiwan,”
Antimicrobial Agents and Chemotherapy, vol. 44, pp. 1438–
1442, 2000.
[ 2 2 ]J .K .R a s h e e d ,C .J a y ,B .M e t c h o c k ,e ta l . ,“ E v o l u t i o no f
extended-spectrum β-lactam resistance (SHV-8) in a strain
of Escherichia coli during multiple episodes of bacteremia,”
Antimicrobial Agents and Chemotherapy, vol. 41, pp. 647–653,
1997.
[23] E. W. Koneman, S. D. Allen, W. M. Janda, P. C. Schreck-
enberger, and W. C. winn, Color Atlas and Textbook of
Diagnostic Microbiology, JB Lippincott, Philadelphia, Pa, USA,
4th edition, 1992.
[ 2 4 ]P .R .M u r r a y ,E .J .B a r o n ,M .A .P f a l l e r ,e ta l . ,E d s . ,Manual
of Clinical Microbiology, American Society for Microbiology,
Washington, DC, USA, 7th edition, 1999.
[25] E. J. Baron and S. M. Finegold, “Methods for testing antimi-
crobial eﬀectiveness,” in Baily& Scott’s Diagnostic Microbiol-
ogy, pp. 171–194, The C.V. Mosby Company, St. Louis, Mo,
USA, 1990.
[26] D. G. Evans, D. J. Evans, and H. L. DuPont, “Virulence factors
of Enterotoxigenic Escherichia coli,” The Journal of Infectious
Diseases, vol. 136, pp. S118–S123, 1977.
[27] National Committee for Clinical Laboratory Standards,
“Methods for dilution antimicrobial susceptibility tests for
bacteria that grow aerobically,” Approved standard M7–A5
and informational supplement M100–S10, National Commit-
tee for Clinical Laboratory Standards, Wayne, Pa, USA, 2000.
[28] V. Jarlier, M. H. Nicolas, G. Fournier, and A. Philippon,
“Extended broad-spectrum β-lactamases conferring transfer-
able resistance to newer β-lactam agents in Enterobacteriaceae:
hospital prevalence and susceptibility patterns,” Reviews of
Infectious Diseases, vol. 10, no. 4, pp. 867–878, 1988.
[29] M. T. Youssef, H. I. Malkawi, A. A. Shurman, and A. O.
Andremont, “Molecular typing of multiresistant Klebsiella
pneumoniae isolated from children from northern Jordan,”
Journal of Tropical Pediatrics, vol. 45, no. 5, pp. 271–277, 1999.
[30] A. A. Shehabia, A. Mahafzah, I. Baadran, F. A. Qadar, and
N. Dajani, “High incidence of Klebsiella pneumoniae clinical
isolatestoextended-spectrumβ-lactamdrugsinintensivecare
units,” Diagnostic Microbiology and Infectious Disease, vol. 36,
no. 1, pp. 53–56, 2000.
[31] P. A. Bradford, “Extended-spectrum β-lactamases in the 21st
century: characterization, epidemiology, and detection of this
important resistance threat,” Clinical Microbiology Reviews,
vol. 14, no. 4, pp. 933–951, 2001.
[32] T. Spanu, F. Luzzaro, M. Perilli, et al., “Occurrence of
extended-spectrum β-lactamases in members of the family
Enterobacteriaceae in Italy: implications for resistance to β-
lactams and other antimicrobial drugs,” Antimicrobial Agents
and Chemotherapy, vol. 46, no. 1, pp. 196–202, 2002.
[33] H.Wang,S.Kelkar,W.Wu,M.Chen,andJ.P.Quinn,“Clinical
isolatesofEnterobacteriaceaeproducingextended-spectrumβ-
lactamases: prevalence of CTX-M-3 at a hospital in China,”
Antimicrobial Agents and Chemotherapy,v o l .4 7 ,n o .2 ,p p .
790–793, 2003.
[34] A. A. Kader and K. Angamuthu, “Extended-spectrum β-
lactamases in urinary isolates of Escherichia coli, Klebsiella
pneumoniae and other gram-negative bacteria in a hospital in8 International Journal of Microbiology
Eastern Province, Saudi Arabia,” Saudi Medical Journal, vol.
26, no. 6, pp. 956–959, 2005.
[35] E. M. Mokaddas, A. A. Abdulla, S. Shati, and V. O. Rotimi,
“The technical aspects and clinical signiﬁcance of detect-
ing extended-spectrum β-lactamase-producing Enterobacte-
riaceae at a tertiary-care hospital in Kuwait,” Journal of
Chemotherapy, vol. 20, no. 4, pp. 445–451, 2008.